Immunosuppressive and immunomodulatory therapies for idiopathic inflammatory myopathies

<p><strong>Objectives:</strong> This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. This protocol is for two separate reviews to assess the effects (benefits and harms) of immunosuppressant and immunomodulatory treatments for the idiopathic infl...

Olles dieđut

Bibliográfalaš dieđut
Váldodahkkit: Raaphorst, J, Gullick, NJ, Pipitone, N, Shokraneh, F, Brassington, R, Ali, SS, Gordon, PA
Materiálatiipa: Journal article
Giella:English
Almmustuhtton: Cochrane Collaboration 2023
Govvádus
Čoahkkáigeassu:<p><strong>Objectives:</strong> This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. This protocol is for two separate reviews to assess the effects (benefits and harms) of immunosuppressant and immunomodulatory treatments for the idiopathic inflammatory myopathies.</p> <p><strong>Targeted treatments:</strong> To assess the effects (benefits and harms) of targeted immunosuppressant and immunomodulatory treatments for the idiopathic inflammatory myopathies: dermatomyositis (DM, including juvenile dermatomyositis, jDM), immune mediated necrotising myopathy (IMNM), anti-synthetase syndrome (ASS), overlap-myositis (OM) and polymyositis (PM). We will also include cancer-related myositis and amyopathic dermatomyositis.</p> <p><strong>Non-targeted treatments:</strong> To assess the effects (benefits and harms) of non-targeted immunosuppressant and immunomodulatory treatments for the idiopathic inflammatory myopathies: dermatomyositis (DM, including juvenile dermatomyositis, jDM), immune mediated necrotising myopathy (IMNM), anti-synthetase syndrome (ASS), overlap-myositis (OM) and polymyositis (PM). We will also include cancer-related myositis and amyopathic dermatomyositis.</p>